免疫因子与经动脉化疗联合介入治疗晚期肺癌

A Study on the Treatment of Advanced Lung Cancer with Combination of Immunotherapy and Chemotherapy

晚期肺癌疗效甚差，其综合治疗仍是目前临床研究的重点，对17例失去手术机会的晚期肺癌进行支气管动脉灌注化疗（BAI）和肿瘤体内局部免疫治疗即双介入治疗（A组），并与同期肺癌10例单纯肿瘤体内局部免疫治疗（B组）、16例单纯BAI治疗（C组）、18例传统化疗（D组）比较疗效，A组完全缓解（CR）2例，部分缓解（PR）13例，近期有效率CR＋PR83．33％，明显优于B组CR＋PR50．00％、C组CR＋PR56．25％和D组CR＋PR33．33％，有统计学意义。A组6例重获Ⅱ期手术适应证，2例手术切除术后病理显示癌细胞大片变性、坏死。单纯局部免疫治疗方法简单，近期疗效接近C、D两组，毒副作用少。双介入治疗晚期肺癌具有较大的应用价值，为晚期肺癌提供了新的有效、简便的治疗方法。

The result of treatment for advanced lung cancer is by far unsatisfactory. Combination therapy remains a focus of clinical research. In this study, 17inoperable advanced lung cancer patients were treated with perfusion of chemotherapeutic agents via bronchial artery in combination with intratumoral interleukin-2immunotherapy (group A). The reuslts were compared with 1)those obtained from 10 patients with only intratumoral immunotherapy (group B); 2) 16 patients only with perfusion of chemotherapeutic agents into to bronchial artery (group C) ; and 3) 18 patients with conventional systemic chemotherapy (group D). The results showed that 2 CR 13 PR were observed in group A with an overall effective rate of 83. 5% which was significantly higher than those in group B (50. 00%), group C (56.25%) and group D (33. 33 % ) (P < 0. 05 ). Intratumoral immunotherapy combined with intrabronchial artery chemotherapy offers satisfying effect in advanced lung cancer.